STOCK TITAN
  1. Home
  2. Sec-filings
  3. URGN
  4. [Form 4] UroGen Pharma Ltd. Insider Trading Activity

Director at UroGen Pharma (NASDAQ: URGN) granted RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

UroGen Pharma Ltd. director Leana Wen reported receiving new equity awards as part of her compensation. She was granted 8,000 restricted stock units, each representing a right to receive one ordinary share, and 10,000 stock options to purchase ordinary shares at an exercise price of $34.99 per share.

The RSUs and the shares underlying the options will vest in equal quarterly installments over one year, contingent on her continued service under the company’s 2017 Equity Incentive Plan. These are grants and do not involve any open-market buying or selling of shares.

Positive

  • None.

Negative

  • None.
Insider WEN LEANA
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right ot buy) 10,000 $0.00 --
Grant/Award Restricted Stock Unit 8,000 $0.00 --
Holdings After Transaction: Stock Option (right ot buy) — 10,000 shares (Direct, null); Restricted Stock Unit — 8,000 shares (Direct, null)
Footnotes (1)
  1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Restricted stock units granted 8,000 units RSU grant to director on June 22, 2026
Stock options granted 10,000 options Option grant to director on June 22, 2026
Option exercise price $34.99 per share Stock option strike price for ordinary shares
Option expiration date June 22, 2036 Expiration of director stock options
Underlying shares for RSUs 8,000 shares Each RSU represents one ordinary share
Underlying shares for options 10,000 shares Ordinary shares subject to stock options
Restricted Stock Unit financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Continuous Service financial
"subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan)"
2017 Equity Incentive Plan financial
"as defined in the 2017 Equity Incentive Plan through such vesting dates"
stock option financial
"The shares underlying the stock option will vest in equal quarterly installments"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WEN LEANA
(Last)(First)(Middle)
400 ALEXANDER PARK DRIVE
(Street)
PRINCETON NEW JERSEY 08540
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right ot buy)$34.9906/22/2026A10,000 (1)06/22/2036Ordinary Shares10,000$010,000D
Restricted Stock Unit(2)06/22/2026A8,000 (3) (3)Ordinary Shares8,000$08,000D
Explanation of Responses:
1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
2. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
3. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
/s/ Jason D. Smith, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did UroGen Pharma (URGN) director Leana Wen report in this Form 4?

Leana Wen reported receiving equity compensation awards from UroGen Pharma. She was granted 8,000 restricted stock units and 10,000 stock options, both tied to the company’s ordinary shares and subject to a one-year quarterly vesting schedule based on continued service.

How many restricted stock units did Leana Wen receive from UroGen Pharma (URGN)?

Leana Wen received 8,000 restricted stock units from UroGen Pharma. Each RSU represents a contingent right to receive one ordinary share, vesting in equal quarterly installments over one year, provided she maintains Continuous Service under the 2017 Equity Incentive Plan.

What are the terms of the UroGen Pharma (URGN) stock options granted to Leana Wen?

Leana Wen was granted 10,000 stock options to buy UroGen Pharma ordinary shares at $34.99 per share. These options vest in equal quarterly installments over one year and expire on June 22, 2036, assuming she continues to meet the plan’s service requirements.

Does this UroGen Pharma (URGN) Form 4 show any open-market stock purchases or sales?

The Form 4 reports only grant or award acquisitions of RSUs and stock options, not open-market trades. It shows no purchases or sales of shares in the market, only compensation-related equity awards that vest over time based on continued service.

How do the RSUs granted to Leana Wen at UroGen Pharma (URGN) vest?

The RSUs vest in equal quarterly installments over one year. Each installment is contingent on Leana Wen’s Continuous Service, as defined in UroGen Pharma’s 2017 Equity Incentive Plan, through each applicable vesting date before shares are delivered.